TSXV:BTI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. More Details


Snowflake Analysis

Limited growth with weak fundamentals.

Share Price & News

How has Bioasis Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BTI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.5%

BTI

6.0%

CA Biotechs

-0.6%

CA Market


1 Year Return

55.6%

BTI

80.0%

CA Biotechs

-7.7%

CA Market

Return vs Industry: BTI underperformed the Canadian Biotechs industry which returned 77.6% over the past year.

Return vs Market: BTI exceeded the Canadian Market which returned -7.8% over the past year.


Shareholder returns

BTIIndustryMarket
7 Day10.5%6.0%-0.6%
30 Day3.7%20.4%-1.1%
90 Day68.0%6.8%5.6%
1 Year55.6%55.6%80.0%80.0%-4.4%-7.7%
3 Year-58.0%-58.0%54.5%54.5%9.1%-1.5%
5 Year-67.7%-67.7%-5.2%-5.2%44.6%22.4%

Price Volatility Vs. Market

How volatile is Bioasis Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bioasis Technologies undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Bioasis Technologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bioasis Technologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BTI's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Bioasis Technologies regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Bioasis Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

70.6%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BTI's forecast earnings growth is above the savings rate (1.7%).

Earnings vs Market: Insufficient data to determine if BTI's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BTI's revenue (70.6% per year) is forecast to grow faster than the Canadian market (5.6% per year).

High Growth Revenue: BTI's revenue (70.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BTI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bioasis Technologies performed over the past 5 years?

-9.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BTI is currently unprofitable.

Growing Profit Margin: BTI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BTI is unprofitable, and losses have increased over the past 5 years at a rate of 9.9% per year.

Accelerating Growth: Unable to compare BTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: BTI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Bioasis Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: BTI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BTI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BTI has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BTI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BTI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BTI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.4% each year


Next Steps

Dividend

What is Bioasis Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BTI's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Deborah Rathjen (62 yo)

1.5yrs

Tenure

CA$105,352

Compensation

Dr. Deborah Ann Rathjen, B.Sc. (Hons.), Ph.D., M.A.I.C.D., FTSE, Q.C. has been the President and Chief Executive Officer of Bioasis Technologies Inc. since March 11, 2019. Dr. Rathjen served as the Chief E ...


Leadership Team

NamePositionTenureCompensationOwnership
Deborah Rathjen
Executive Chairman1.5yrsCA$105.35k0.26%
CA$ 75.0k
Christine Antalik
Chief Financial Officer1.67yrsCA$304.70kno data
Graeme Dick
Director of Investor Relationsno datano datano data
Kim Elton
Director of Marketingno datano datano data
Doug Williams
Executive VP & Chief Business Officer3.08yrsno datano data
Mei Tian
VP & Head of External Researchno datano datano data
May Orfali
Consultant Chief Medical Officer0.50yrno datano data

1.6yrs

Average Tenure

Experienced Management: BTI's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Deborah Rathjen
Executive Chairman1.5yrsCA$105.35k0.26%
CA$ 75.0k
David Wurzer
Independent Lead Director1.75yrsCA$152.42k0.079%
CA$ 22.5k
Jeffrey Cummings
Member of Scientific Advisory Board3yrsno datano data
John Wikswo
Member of Scientific Advisory Board3yrsno datano data
John Krystal
Chairman of Scientific Advisory Board3yrsno datano data
Mario Saltarelli
Independent Non-Executive Director1.33yrsno datano data
Hope Rugo
Member of Medical Oncology Advisory Board0.75yrno datano data
Jack Hoppin
Member of Scientific Advisory Board2.25yrsno datano data
John de Groot
Member of Medical Oncology Advisory Board0.75yrno datano data
Sue O'Connor
Member of Scientific Advisory board2.25yrsno datano data
John Curran
Independent Director2.17yrsCA$152.42k0.079%
CA$ 22.5k
Javier Cortés
Member of Medical Oncology Advisory Board0.75yrno datano data

2.2yrs

Average Tenure

62yo

Average Age

Experienced Board: BTI's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.5%.


Top Shareholders

Company Information

Bioasis Technologies Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bioasis Technologies Inc.
  • Ticker: BTI
  • Exchange: TSXV
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$28.545m
  • Shares outstanding: 67.96m
  • Website: https://www.bioasis.us

Location

  • Bioasis Technologies Inc.
  • 14 Water Street
  • Guilford
  • Connecticut
  • 6437
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BTITSXV (TSX Venture Exchange)YesCommon SharesCACADMar 2008
BIOA.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2008
107DB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2008

Biography

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/21 06:16
End of Day Share Price2020/09/18 00:00
Earnings2020/05/31
Annual Earnings2020/02/29


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.